Regulatory anticipation of postmarket safety problems for novel medicines approved by the EMA between 2001 and 2010: a cross‐sectional study

The aim of the study is to describe preapproval safety concerns expressed by the European Medicines Agency (EMA) following regulatory review and to compare those concerns with subsequent issuance of postmarket safety communications.

[1]  H. Leufkens,et al.  Risk Management Plans as a Tool for Proactive Pharmacovigilance: A Cohort Study of Newly Approved Drugs in Europe , 2014, Clinical pharmacology and therapeutics.

[2]  R. Friedman.  Antidepressants' black-box warning--10 years later. , 2014, The New England journal of medicine.

[3]  J. Ross,et al.  Inconsistencies among European Union Pharmaceutical Regulator Safety Communications: A Cross-Country Comparison , 2014, PloS one.

[4]  Harlan M. Krumholz,et al.  Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005-2012. , 2014, JAMA.

[5]  A. Hoes,et al.  Number of Patients Studied Prior to Approval of New Medicines: A Database Analysis , 2013, PLoS medicine.

[6]  H. Eichler,et al.  Additional safety risk to exceptionally approved drugs in Europe? , 2011, British journal of clinical pharmacology.

[7]  A. Breckenridge,et al.  European Perspective on Risk Management and Drug Safety , 2011, Clinical pharmacology and therapeutics.

[8]  A. Conforti,et al.  Risk Management Plans: are they a tool for improving drug safety? , 2010, European Journal of Clinical Pharmacology.

[9]  H. Leufkens,et al.  Safety-Related Regulatory Actions for Orphan Drugs in the US and EU , 2010, Drug safety.

[10]  Huub Schellekens,et al.  Safety-related regulatory actions for biologicals approved in the United States and the European Union. , 2008, JAMA.

[11]  R. Temple,et al.  Drug-review deadlines and safety problems. , 2008, The New England journal of medicine.

[12]  M. Olson.  The risk we bear: the effects of review speed and industry user fees on new drug safety. , 2008, Journal of health economics.

[13]  Jerry Avorn,et al.  Paying for drug approvals--who's using whom? , 2007, The New England journal of medicine.